港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

醫美概念股

1,167.510

+13.8911.20%

漲家數：6

跌家數：4

平家數：3

市盈率：- -

高：1,171.927

開：1,157.168

低：1,156.786

收：1,153.620

成交量：2,126.45萬

成交額：2.53億

市值：1,936.67億

流通市值：1,447.63億

資料載入中...

總覽新聞資訊

上海復星醫藥（集團）股份有限公司關於控股子公司許可協議的進展公告

康哲藥業(867.HK/8a8.SG)：磷酸魯索替尼乳膏新增特應性皮炎適應症上市申請獲中國藥監局受理並納入優先審評

山河藥輔遭復星醫藥減持1%，套現約3819萬元，近年來減持動作頻繁

深圳商报·读创

春節假期中緬邊境瑞麗口岸出入境旅客逾11萬人次

中国新闻网

春節文旅消費創新高，復星主業基本盤穩固馬年展現強勁增長勢頭

凤凰网财经

復星醫藥（600196）披露控股子公司鹽酸莫託咪酯注射液藥品註冊申請獲受理，2月24日股價下跌0.15%

康哲藥業蘆可替尼乳膏新增適應症上市申請獲受理並納入優先審評

康哲藥業蘆可替尼磷酸酯乳膏治療特應性皮炎新藥申請獲中國國家藥監局受理

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏增加特應性皮炎(AD)適應症中國上市許可申請獲受理並獲納入優先審評

醫思健康：截至二零二五年三月三十一日止年度年報之補充公告

香港交易所

醫思健康02月24日主力淨流出12萬元散户資金買入

時代天使(06699)：歐洲法院對於特定軟件功能的初步裁定對用户影響甚微

康哲藥業(0867.HK)：商業化能力卓越創新轉型迎業績長周期增長

65款國產1類新藥有望今年上市！涉恒瑞、悦康、以嶺、科倫...

每日沽空追蹤 | 現代牙科 02月23日沽空量成交1000股，沽空比例為0.21%

每日沽空追蹤 | 三生製藥 02月23日沽空量成交77.3萬股，沽空比例為18.64%

每日沽空追蹤 | 康哲藥業 02月23日沽空量成交2.7萬股，沽空比例為1.01%

每日沽空追蹤 | 四環醫藥 02月23日沽空量成交4.4萬股，沽空比例為0.55%

三生製藥02月23日獲主力加倉1506.4萬元

四環醫藥02月23日主力淨流出180.8萬元散户資金買入

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1593/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":1167.5104,"timestamp":1771991976862,"preClose":1153.6196,"halted":0,"volume":21264541,"delay":0,"changeRate":0.012041,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午間休市","change":13.890747,"latestTime":"02-25 12:00:00","open":1157.1675,"high":1171.9274,"low":1156.7864,"amount":252606133,"amplitude":0.013125,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771995600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771983000000,1771992000000],[1771995600000,1772006400000]],"pbRate":1.670017,"peRate":24.035874,"turnoverRate":0.001063,"increases":6,"decrements":4,"flats":3,"marketCap":193666652632,"floatMarketCap":144763385816},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1171.9274,"amplitude":0.013125,"preClose":1153.6196,"low":1156.7864,"pbRate":"1.670017","latestPrice":1167.5104,"volume":21264541,"delay":0,"open":1157.1675,"prevYearClose":1094.978,"prevWeekClose":1191.344,"prevMonthClose":1146.099,"prevQuarterClose":1094.978,"fiveDayClose":1180.813,"twentyDayClose":1140.571,"sixtyDayClose":1249.354,"secType":"PLATE","market":"HK","turnoverRate":0.001063,"peRate":24.035874,"marketCap":193666652632,"floatMarketCap":144763385816,"timestamp":1771991976862,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":6,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614226721","title":"上海復星醫藥（集團）股份有限公司關於控股子公司許可協議的進展公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2614226721","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614226721?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 06:37","pubTimestamp":1771972620,"startTime":"0","endTime":"0","summary":"上海复星医药公告其控股子公司许可协议进展：2014-2024年，复宏汉霖先后与KGbio、Abbott签订许可协议，授予斯鲁利单抗注射液在东南亚、中东、北非、拉丁美洲等地区的独家商业化许可。2026年2月24日，复宏汉霖与KGbio签订协议，终止《2023年独家许可协议》及KGbio终止区域独家商业化许可；同日，与Abbott签订修正案，扩展许可区域并增加里程碑付款，此次进展无需提请董事会及股东会批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225064027a4c468ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225064027a4c468ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1593","BK1191"],"gpt_icon":0},{"id":"1182063591","title":"康哲藥業(867.HK/8a8.SG)：磷酸魯索替尼乳膏新增特應性皮炎適應症上市申請獲中國藥監局受理並納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=1182063591","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182063591?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 21:37","pubTimestamp":1771940220,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其磷酸鲁索替尼乳膏用于新增适应症——特应性皮炎（AD）的新药上市申请（NDA），已获得中国国家药品监督管理局的正式受理，并被纳入优先审评程序。这一进展有望加速该产品在中国市场的上市进程，为特应性皮炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867","SG9999015952.SGD","SG9999015986.USD","SG9999004220.SGD","SG9999015978.USD","IE00BVYPNQ40.USD","BK1191","IE00BYV24P56.USD","LU2488822045.USD","BK1593","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","SG9999015945.SGD"],"gpt_icon":0},{"id":"2613471677","title":"山河藥輔遭復星醫藥減持1%，套現約3819萬元，近年來減持動作頻繁","url":"https://stock-news.laohu8.com/highlight/detail?id=2613471677","media":"深圳商报·读创","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613471677?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 20:19","pubTimestamp":1771935540,"startTime":"0","endTime":"0","summary":"2月24日晚间，山河药辅(300452)发布公告称，公司持股5%以上股东复星医药在2025年11月24日至2026年1月15日期间减持了232.57万股，占公司总股本的1.00%，减持均价16.42元/股，套现约3819万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652951387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600196","BK1515","BK0175","BK0177","BK0012","BK0196","BK0187","BK0183","BK0060","BK0188","BK0028","300452","BK0239","BK1191","BK0096","BK1593","02196"],"gpt_icon":0},{"id":"2613715815","title":"春節假期中緬邊境瑞麗口岸出入境旅客逾11萬人次","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715815","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715815?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:52","pubTimestamp":1771933920,"startTime":"0","endTime":"0","summary":"春节假期，瑞丽口岸出入境客流主要以在外中国旅客返乡团圆、出境探亲访友以及缅甸旅客入境观光、体验中国年味为主，客流高峰集中、需求多元多样。2月15日，经该口岸国门通道、中缅街通道出入境旅客突破1.53万人次，创春节期间单日峰值。为精准应对春运客流高峰，瑞丽出入境边防检查站及时发布通关指引、客流预警，开足查验通道，最大限度提升通关效能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnxnuk5891157.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnxnuk5891157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","02135","BK1593"],"gpt_icon":0},{"id":"2614411657","title":"春節文旅消費創新高，復星主業基本盤穩固馬年展現強勁增長勢頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2614411657","media":"凤凰网财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614411657?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:46","pubTimestamp":1771933560,"startTime":"0","endTime":"0","summary":"2026年开年以来，随着创新成果的商业化落地及全球化运营的深入，复星国际核心主业延续了此前强劲的增长势头，在文旅、消费、创新药等赛道迎来新突破。文旅消费作为复星的核心主业之一，马年春节期间多条产品线展现了出强劲的增长势头。数据显示，2025年前三季度，复星医药的创新药品收入已超67亿元，同比增长18.09%。数据显示，2025年上半年，复星国际总债务占总资本比率53%，债务成本进一步下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224195109a4c2ec72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224195109a4c2ec72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1593","BK1191","BK1230","BK1574","BK1161","00656","06978"],"gpt_icon":0},{"id":"2613897792","title":"復星醫藥（600196）披露控股子公司鹽酸莫託咪酯注射液藥品註冊申請獲受理，2月24日股價下跌0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613897792","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613897792?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 18:08","pubTimestamp":1771927718,"startTime":"0","endTime":"0","summary":"近日，上海复星医药(集团)股份有限公司控股子公司锦州奥鸿药业有限责任公司提交的盐酸莫托咪酯注射液药品注册申请已获国家药品监督管理局受理，拟定适应症为麻醉诱导和短时手术麻醉。该新药为静脉全身麻醉1类新药，2014年列入“重大新药创制”科技重大专项。截至2026年1月，本集团累计研发投入约1.89亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32024022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","02196","BK0012","BK0175","BK0188","BK0028","BK0196","BK0183","BK0187","BK0060","BK0239","BK0096","BK1593","BK1515","600196"],"gpt_icon":0},{"id":"1174404047","title":"康哲藥業蘆可替尼乳膏新增適應症上市申請獲受理並納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=1174404047","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174404047?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:54","pubTimestamp":1771926861,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其芦可替尼乳膏新增适应症（特应性皮炎）的上市申请已获中国国家药品监督管理局正式受理，并被纳入优先审评程序。此举有望加速该产品在中国市场的准入进程，为特应性皮炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMCWC346.EUR","LU2488822045.USD","SG9999015952.SGD","IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999015978.USD","SG9999015986.USD","00867","BK1191","SG9999015945.SGD","SG9999004220.SGD","BK1593","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"1125052120","title":"康哲藥業蘆可替尼磷酸酯乳膏治療特應性皮炎新藥申請獲中國國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1125052120","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125052120?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:49","pubTimestamp":1771926587,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其用于治疗特应性皮炎的芦可替尼磷酸酯乳膏新药申请，已正式获得中国国家药品监督管理局的受理。这一进展标志着该药物在中国上市审批流程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","IE00BVYPNP33.GBP","SG9999015952.SGD","IE00BVYPNQ40.USD","LU2488822045.USD","00867","BK1191","IE00BMCWC346.EUR","IE00BYV24P56.USD","SG9999015978.USD","SG9999004220.SGD","IE00BGHQDM52.EUR","SG9999015945.SGD","SG9999015986.USD"],"gpt_icon":0},{"id":"2613871794","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏增加特應性皮炎(AD)適應症中國上市許可申請獲受理並獲納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871794","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613871794?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:49","pubTimestamp":1771926559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年2月24日获得中国国家药品监督管理局受理磷酸芦可替尼乳膏轻中度特应性皮炎的新药上市许可申请。且该项NDA因“符合儿童生理特征的儿童用药品新品种、剂型和规格”，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1574","LU2488822045.USD","IE00BVYPNP33.GBP","BK1161","IE00BMCWC346.EUR","SG9999015986.USD","SG9999015978.USD","IE00BGHQDM52.EUR","BK1191","IE00BVYPNQ40.USD","BK1593","SG9999015952.SGD","SG9999004220.SGD","BK4132","159992","00867","SG9999015945.SGD","IE00BYV24P56.USD","AD"],"gpt_icon":0},{"id":"2614735637","title":"醫思健康：截至二零二五年三月三十一日止年度年報之補充公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2614735637","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614735637?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:31","pubTimestamp":1771921865,"startTime":"0","endTime":"0","summary":"医思健康发布截至2025年3月31日止年度年报之补充公告，就股份奖励计划作出进一步说明。根据2016年6月27日采纳的股份奖励计划，董事会授出奖励股份的面值不得超过公司已发行股本的10%。于本公告日期，公司并无任何尚未行使或未归属的奖励股份，截至2025年3月31日可供发行的奖励股份总数为1.11亿股。公司强调，未来授出任何奖励股份时将全面遵守上市规则要求，包括不少于12个月的归属期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225023148a71ad52a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225023148a71ad52a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1215","02138","BK1593","BK1511"],"gpt_icon":0},{"id":"2614874619","title":"醫思健康02月24日主力淨流出12萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614874619","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614874619?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 16:15","pubTimestamp":1771920927,"startTime":"0","endTime":"0","summary":"02月24日, 医思健康股价跌4.84%，报收0.59元，成交金额59.8万元，换手率0.08%，振幅4.84%，量比4.47。医思健康今日主力资金净流出12万元，上一交易日主力净流出0万元。该股近5个交易日下跌3.23%，主力资金累计净流出12万元；近20日主力资金累计净流出10.1万元，其中净流出天数为2日。该股主力净额占比0.02%，港股市场排名2468/2720。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161650a7190895&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161650a7190895&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1215","02138","BK1593","BK1511"],"gpt_icon":0},{"id":"2613752227","title":"時代天使(06699)：歐洲法院對於特定軟件功能的初步裁定對用户影響甚微","url":"https://stock-news.laohu8.com/highlight/detail?id=2613752227","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613752227?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 09:47","pubTimestamp":1771897645,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，时代天使科技有限公司表示，德国杜塞尔多夫统一专利法院下达临时禁令，要求公司暂停使用自动更新方案功能中的特定模块，这对使用时代天使隐形矫治产品的医生和患者影响甚微。时代天使表示，正畸治疗方案设计软件iOrtho中的Live Now功能不存在侵犯爱齐科技任何有效专利的情况。杜塞尔多夫统一专利法院作出的裁定仅为一审，并非最终裁定，时代天使有信心推翻这一裁定。时代天使长期获得医生的高满意度评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1587","06699","BK1100","BK1583","BK4588","VGT","BK4585"],"gpt_icon":0},{"id":"2613748055","title":"康哲藥業(0867.HK)：商業化能力卓越 創新轉型迎業績長周期增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2613748055","media":"信达证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613748055?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 00:00","pubTimestamp":1771862400,"startTime":"0","endTime":"0","summary":"国内商业化能力卓越，海外东南亚市场研产销布局完备公司具备卓越的、覆盖全链路的商业化能力，拥有约4700 人的专业学术推广团队，网络深度覆盖中国超5 万家医院及医疗机构、约30 万家零售药店及主流电商平台，能够高效驱动产品放量。国际化战略方面，公司前瞻性地在东南亚市场构建了完整的研发+注册与商业化+生产一体化布局，为公司打开了长期、可持续的第二增长曲线。我们看好公司中长期成长性，首次覆盖给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224202659a4c309cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224202659a4c309cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BMCWC346.EUR","LU2488822045.USD","SG9999015952.SGD","IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999015978.USD","SG9999015986.USD","00867","BK1191","SG9999015945.SGD","SG9999004220.SGD","BK1593","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2613475340","title":"65款國產1類新藥有望今年上市！涉恒瑞、悦康、以嶺、科倫...","url":"https://stock-news.laohu8.com/highlight/detail?id=2613475340","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613475340?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 18:59","pubTimestamp":1771844347,"startTime":"0","endTime":"0","summary":"据不完全统计，恒瑞医药的SHR4640片、悦康药业的紫花温肺止嗽颗粒、以岭药业的芪桂络痹通片、三生制药的重组红细胞生成刺激蛋白注射液......65款国产1类新药有望于今年内获批上市。恒瑞至少有5款1类新药有望于2026年获批上市，涉及消化系统、免疫疾病、肌肉-骨骼、妇科等治疗领域。目前，悦康药业已有3款中药1类新药报产在审、上市可期。芪桂络痹通片已于2025年3月申报NDA获受理，有望于今年3月底传来喜讯。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223191152a715bfc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223191152a715bfc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2613733433","title":"每日沽空追蹤 | 現代牙科 02月23日沽空量成交1000股，沽空比例為0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733433","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733433?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:30","pubTimestamp":1771835434,"startTime":"0","endTime":"0","summary":"现代牙科北京时间02月23日，股价较前一交易日持平，卖空量成交1000股，较上一交易日减少95.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163443a4be7e21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163443a4be7e21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03600","BK1593","BK1100"],"gpt_icon":0},{"id":"2613534797","title":"每日沽空追蹤 | 三生製藥 02月23日沽空量成交77.3萬股，沽空比例為18.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613534797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613534797?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:30","pubTimestamp":1771835422,"startTime":"0","endTime":"0","summary":"三生制药北京时间02月23日，股价较前一交易日持平，卖空量成交77.3万股，较上一交易日减少53.59%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163245a71563b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163245a71563b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","01530","BK1593","HK0000165453.HKD"],"gpt_icon":0},{"id":"2613736053","title":"每日沽空追蹤 | 康哲藥業 02月23日沽空量成交2.7萬股，沽空比例為1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613736053","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613736053?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:30","pubTimestamp":1771835416,"startTime":"0","endTime":"0","summary":"康哲药业北京时间02月23日，涨1.98%，卖空量成交2.7万股，较上一交易日减少87.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163140a71562db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163140a71562db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BVYPNQ40.USD","00867","SG9999015978.USD","SG9999015952.SGD","SG9999015986.USD","BK1191","SG9999015945.SGD","IE00BMCWC346.EUR","IE00BYV24P56.USD","IE00BGHQDM52.EUR","SG9999004220.SGD","BK1593","LU2488822045.USD","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2613732633","title":"每日沽空追蹤 | 四環醫藥 02月23日沽空量成交4.4萬股，沽空比例為0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613732633","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613732633?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:30","pubTimestamp":1771835413,"startTime":"0","endTime":"0","summary":"四环医药北京时间02月23日，股价较前一交易日持平，卖空量成交4.4万股，较上一交易日减少87.43%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163105a7156259&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163105a7156259&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1191","BK1600","BK1593","BK1515"],"gpt_icon":0},{"id":"2613753415","title":"三生製藥02月23日獲主力加倉1506.4萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753415","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613753415?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:16","pubTimestamp":1771834564,"startTime":"0","endTime":"0","summary":"02月23日，三生制药股价收平报23.90元，成交金额9917.6万元，换手率0.16%，振幅3.01%，量比0.46。三生制药今日主力资金净流入1506.4万元，上一交易日主力净流入1558.8万元。该股近5个交易日下跌0.91%，主力资金累计净流入2245.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1.1亿元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223162131a4be7540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223162131a4be7540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","HK0000165453.HKD","BK1161","BK1583","BK1593"],"gpt_icon":0},{"id":"2613732686","title":"四環醫藥02月23日主力淨流出180.8萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2613732686","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613732686?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:15","pubTimestamp":1771834556,"startTime":"0","endTime":"0","summary":"02月23日，四环医药股价收平报1.69元，成交金额1354.2万元，换手率0.09%，振幅2.96%，量比0.19。四环医药今日主力资金净流出180.8万元，上一交易日主力净流入28.7万元。该股近5个交易日上涨1.20%，主力资金累计净流出376.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.1亿元，其中净流入天数为13日。该股主力净额占比0.01%，港股市场排名2566/2717。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223162031a7155b41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223162031a7155b41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1600","BK1191","BK1515","BK1593"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}]}}